MANE

Veradermics Inc

May 15 • 04:00PM ET

99.72

-6.35 -5.99 %

Healthcare • Biotechnology • USA • Mid • NYSE

| Held by: VTI VXF SCHA JGRO LFSC TOS ITOT FPX SCHB VTWO

Index	-	P/E	-	EPS (ttm)	-	Insider Own	23.01%	Shs Outstand	37.34M	Perf Week	-6.05%
Market Cap	4.17B	Forward P/E	-	EPS next Y	-2.58	Insider Trans	42.02%	Shs Float	32.17M	Perf Month	34.54%
Enterprise Value	3.78B	PEG	-	EPS next Q	-0.67	Inst Own	51.66%	Short Float	6.40%	Perf Quarter	129.45%
Income	-	P/S	-	EPS this Y	13.11%	Inst Trans	27.69%	Short Ratio	3.94	Perf Half Y	-
Sales	-	P/B	9.50	EPS next Y	12.51%	ROA	-	Short Interest	2.06M	Perf YTD	164.16%
Book/sh	10.49	P/C	10.66	EPS next 5Y	26.34%	ROE	-	52W High	117.71 -15.28%	Perf Year	-
Cash/sh	9.35	P/FCF	-	EPS past 3/5Y	-117.94% -	ROIC	-	52W Low	32.00 211.63%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.53% 10.06%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	8.35	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	59.12	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.77	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	59.12	EPS Q/Q	-	SMA20	3.16%	Beta	-	Target Price	131.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	31.64%	Rel Volume	0.91	Prev Close	106.07
Employees	21	LT Debt/Eq	0.00	Earnings	May 12 BMO	SMA200	50.38%	Avg Volume	523.23K	Price	99.72
IPO	Feb 04, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-70.56% -	Trades		Volume	476,787	Change	-5.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-02-26	Initiated	Leerink Partners	Outperform	$75
Mar-02-26	Initiated	Jefferies	Buy	$75
Mar-02-26	Initiated	Citigroup	Buy	$85
Mar-02-26	Initiated	Cantor Fitzgerald	Overweight

May-15-26 04:52AM	The IPO Boom Isn't in Tech and AI-Yet (Barrons.com) -5.99%
May-14-26 01:09PM	Cerebras Swings IPO Focus to Tech and AI. But Healthcare and Industrials Still Lead. (Barrons.com)
07:30AM	Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium (Business Wire)
May-12-26 05:13PM	Veradermics: Q1 Earnings Snapshot (Associated Press)
07:30AM	Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (Business Wire)
10:32PM	Loading…
Apr-29-26 10:32PM	Veradermics Announces Pricing of Upsized Public Offering and Private Placement (Business Wire) -7.09%
Apr-27-26 05:26PM	Veradermics Announces Launch of Public Offering (Business Wire) +47.55%
09:52AM	Veradermics Shares Jump 17% on Promising Hair Loss Trial Results (InvestorsHub)
09:31AM	How This Biotech, Up 25%, Is Taking A Page Out Of Rogaine's Playbook (Investor's Business Daily)
07:03AM	A new version of an old drug is helping men grow back some of their hair (MarketWatch)
07:00AM	Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 '302' Clinical Trial in Male Pattern Hair Loss (Business Wire)
Apr-26-26 04:00PM	Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 302 Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss (Business Wire)
Apr-01-26 01:13PM	Squawk Pod: OpenAI's eye-popping raise & hair today, hair forever - 04/01/26 Audio Only (CNBC TV) -6.92%
Mar-30-26 07:30AM	Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates (Business Wire) -7.14%
Mar-18-26 07:00AM	Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting (Business Wire)
07:00AM	Loading…
Mar-03-26 07:00AM	Veradermics to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-26-26 08:04PM	Flagship-Backed Generate Biomedicines Raises $400 Million in IPO (Bloomberg) +6.85%
07:39AM	For the first time in decades, new hair-loss treatments are in the works. Heres how theyre different. (MarketWatch)
Feb-25-26 03:36PM	For the first time in decades, new hair-loss treatments are in the works. Here's how they're different. (MarketWatch)
Feb-16-26 08:40AM	Reddit, KKR, and 2 Biotech IPOs Seeing the Love From Insiders (24/7 Wall St.)
Feb-12-26 08:55AM	NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell (PR Newswire)
Feb-09-26 07:30AM	Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss (Business Wire)
Feb-06-26 04:18PM	Jennifer Garner's Once Upon a Farm Rises Nearly 20% To Wrap Up Busy Week for IPOs (Barrons.com)
Feb-05-26 04:05PM	Veradermics Announces Closing of Full Exercise of Underwriters Option to Purchase Additional Shares in Initial Public Offering (Business Wire)
Feb-04-26 04:12PM	No Revenue? No Problem. Biotech Targeting Hair Loss Doubles in Stock IPO. (Barrons.com)
01:07PM	This week's first IPO is set for a warm Wall Street welcome (MarketWatch)
08:55AM	NYSE Content Update: Disney Names New CEO After Ringing Bell on Main Street USA (PR Newswire)
Feb-03-26 09:57PM	Veradermics Announces Pricing of Upsized Initial Public Offering (Business Wire)

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

CEO & DirectorDr. Reid Waldman M.D.

CFO & TreasurerMr. Dominic Carrano CPA

Chief Technical OfficerDr. Timothy Durso M.D.

General Counsel & SecretaryMr. Michael V. Greco J.D.

Senior Director of Manufacturing Sciences & TechnologyMr. Karl Pruss

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 04 '26	Buy	37.05	155,953	5,778,342	3,648,538	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 05 '26	Buy	37.99	96,200	3,655,079	489,932	Feb 09 06:28 PM
SUVRETTA CAPITAL MANAGEMENT, L	Director	Feb 06 '26	Buy	36.34	30,521	1,109,056	520,453	Feb 09 06:28 PM
Coric Vlad	Director	Feb 05 '26	Buy	17.00	117,646	1,999,982	319,398	Feb 05 07:04 PM
CHILDS JOHN W	Director	Feb 05 '26	Buy	17.00	294,117	4,999,989	2,202,006	Feb 05 07:04 PM
Longitude Capital Partners V,	10% Owner	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM
ENRIGHT PATRICK G	Director	Feb 05 '26	Buy	17.00	1,075,000	18,275,000	2,600,399	Feb 05 07:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MANE

Veradermics Inc

Upgrade your Finviz experience